Response of mucocutaneous lesions to rituximab in a case of melanoma differentiation antigen 5-related dermatomyositis

28Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.
Get full text

Abstract

We report the first case in Western Europe of a person presenting with dermatomyositis associated with melanoma differentiation antigen 5 antibodies. She sequentially developed severe mucocutaneous erythematous and itchy lesions of the face, scalp, neck, knees and recurrent aphthae. In addition she presented painful, periungual, edematous digital lesions and small ulcers with digital necrosis. Her rapidly evolving, near-fatal interstitial lung disease responded to high-dose intravenous cyclophosphamide. However, her recurrent mucocutaneous mani-festations improved only after rituximab administration. Copyright © 2013 S. Karger AG, Base.

Cite

CITATION STYLE

APA

Clottu, A., Laffitte, E., Prins, C., & Chizzolini, C. (2013). Response of mucocutaneous lesions to rituximab in a case of melanoma differentiation antigen 5-related dermatomyositis. Dermatology, 225(4), 376–380. https://doi.org/10.1159/000346573

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free